Paradigm has results from its Phase 2 hay fever trial pending in six weeks.
ACCESS THE FULL PRESENTATION HERE
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”